Methods: In this double-blind trial, we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (27 in persons with 1 weight-related coexisting condition), who did not have diabetes, and randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention
GI symptoms are among the most common side effects of semaglutide
At this writing, only TRIUMPH-4 has been reported by the company
Cookies pouvame, aby sme vm mohli poskytn dobr pouvatesk dojem
353a (Section 503A)
Chian, S., Thapa, R., Chi, Z., Wang, X